Next-Generation Sequencing: Revolutionizing Patient Care in Your Oncology Practice
The age of precision medicine, driven by the capabilities of Next-Generation Sequencing (NGS), is here! The term precision medicine describes medical advances and approaches based on the analysis of an individual’s genetic information and is used as part of their clinical care to help predict how they will respond to a given treatment regimen.
Precision medicine has the potential to offer new possibilities: from prediction of a patient’s cancer risk, to earlier diagnoses and development of novel targeted therapies. In order to translate a patient’s genomic information in a clinically meaningful way, it is essential for oncologists to become acquainted with the capabilities of NGS and how it can facilitate precision medicine in their clinical practice.
For the numerous types of cancer, NGS can offer the ability to simultaneously screen for multiple gene variants without a battery of testing. Using just a very small amount of sample, NGS high-throughput technology analyzes millions of fragments of DNA in parallel with high efficiency, low costs, and short processing times.
NGS is helping to improve cancer diagnostics, prognosis, selection of a more precise and personalized treatment plan, and more accurate treatment adjustments when needed.
Kyowa Kirin is a global specialty pharmaceutical company with US Headquarters based in Bedminster, NJ. The company is focused primarily on developing and commercializing biopharmaceuticals that help improve the health and well-being of people through innovative and state-of-the-art technologies in various therapeutic areas including oncology, neurology, nephrology, and immunology. For additional information, you can visit us at www.kyowakirin.com.
EUSA Pharma is a dynamic, global biopharmaceutical company focused on oncology and rare disease, continuously striving to confront gaps in patient care. Our ambition drives us to deliver medical treatments that deliver real change to improve lives wherever they are needed in the world. As a young, specialty pharmaceutical company, EUSA Pharma is committed to delivering solutions that can have a meaningful effect on life, helping patients across a range of therapy areas.
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,000+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market an internally-discovered product, BRUKINSA® (zanubrutinib) in the United States.
Epizyme, Inc. is a fully integrated biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through transformative epigenetic medicines. In addition to a robust research and discovery pipeline, Epizyme has one commercial oncology product and is exploring the treatment potential of this therapy in investigational clinical trials focused on other conditions. By focusing on the genetic drivers of disease, Epizyme works to match new medicines with the patients who need them. For more information, visit www.epizyme.com.